Literature DB >> 24012576

Rhizarthrosis fourth grade of eaton with hyperextension of the metacarpophalangeal joint.

Omar Faour-Martín1, Miguel Ángel Martín-Ferrero, Jose Antonio Valverde-García, Aurelio Vega-Castrillo, María Ángeles De La Red-Gallego.   

Abstract

INTRODUCTION: Restoration of thumb function with a painfree, stable, and mobile joint with preserved strength are the main goals of treatment of painful arthritis of the thumb. We present our clinical experience in surgical treatment of this disease, in its highest degree of affectation. PRESENTATION OF CASE: A 57-year-old woman presents with a 2-year history of worsening pain at the base of her right, dominant, trapezial-metacarpal (TM) joint. Her thumb metacarpophalangeal (MCP) joint hyperextends 30° with lateral pinch. Radiographs demonstrate Eaton stage IV degenerative changes of her TM joint and no arthritis of her thumb MCP joint. She was successfully treated with a modified Burton-Pellegrini arthroplasty and sesamoidesis to the metacarpal head. DISCUSSION: In cases of advanced rhizarthrosis conventional surgery does not serve to correct deformities of the metacarpophalangeal joint that may affect to the postsurgical outcomes.
CONCLUSION: rhizarthrosis management must be carried out in a global way. When a surgical treatment is planned, all deformities must be taken into account.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Burton; Pellegrini; Surgical management; Thumb

Year:  2013        PMID: 24012576      PMCID: PMC3785934          DOI: 10.1016/j.ijscr.2013.07.028

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


  18 in total

1.  Use of the entire width of the flexor carpi radialis tendon for the ligament reconstruction tendon interposition arthroplasty does not impair wrist function.

Authors:  M M Tomaino; K Coleman
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2000-04

Review 2.  Basal joint arthritis of the thumb.

Authors:  O A Barron; S Z Glickel; R G Eaton
Journal:  J Am Acad Orthop Surg       Date:  2000 Sep-Oct       Impact factor: 3.020

3.  Metacarpophalangeal joint hyperextension and the treatment of thumb basilar joint arthritis.

Authors:  David M Brogan; Sanjeev Kakar
Journal:  J Hand Surg Am       Date:  2012-02-01       Impact factor: 2.230

4.  The modified Burton-Pellegrini method for the treatment of trapeziometacarpal arthritis. Medium-term results.

Authors:  G Pilato; D Gamberoni; M F E Surace; E Baldo; P Cherubino
Journal:  Chir Organi Mov       Date:  2005 Jul-Sep

Review 5.  Total joint arthroplasty for the arthritic thumb carpometacarpal joint.

Authors:  Alejandro Badia
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2008-08

6.  Arthroplasty of the basal joint of the thumb. Long-term follow-up after ligament reconstruction with tendon interposition.

Authors:  M M Tomaino; V D Pellegrini; R I Burton
Journal:  J Bone Joint Surg Am       Date:  1995-03       Impact factor: 5.284

7.  Management of hyperextension of the metacarpophalangeal joint in association with trapeziometacarpal joint osteoarthritis.

Authors:  R J Poulter; T R C Davis
Journal:  J Hand Surg Eur Vol       Date:  2011-03-03

8.  Tendon interposition arthroplasty versus arthrodesis for the treatment of trapeziometacarpal arthritis: a retrospective comparative follow-up study.

Authors:  M A Mureau; R P Rademaker; J A Verhaar; S E Hovius
Journal:  J Hand Surg Am       Date:  2001-09       Impact factor: 2.230

9.  The disabilities of the arm, shoulder and hand (DASH) outcome questionnaire: reliability and validity of the Swedish version evaluated in 176 patients.

Authors:  I Atroshi; C Gummesson; B Andersson; E Dahlgren; A Johansson
Journal:  Acta Orthop Scand       Date:  2000-12

Review 10.  Ligament reconstruction with or without tendon interposition to treat primary thumb carpometacarpal osteoarthritis. Surgical technique.

Authors:  Gabriele Kriegs-Au; Gert Petje; Eva Fojtl; Rudolf Ganger; Ingrid Zachs
Journal:  J Bone Joint Surg Am       Date:  2005-03       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.